Abdel Saci

4.8k total citations · 1 hit paper
32 papers, 3.2k citations indexed

About

Abdel Saci is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Abdel Saci has authored 32 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Surgery and 14 papers in Molecular Biology. Recurrent topics in Abdel Saci's work include Cancer Immunotherapy and Biomarkers (19 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Urinary and Genital Oncology Studies (8 papers). Abdel Saci is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Urinary and Genital Oncology Studies (8 papers). Abdel Saci collaborates with scholars based in United States, Italy and Germany. Abdel Saci's co-authors include Padmanee Sharma, Matthew D. Galsky, Arlene O. Siefker‐Radtke, Andrea Necchi, Alex Azrilevich, Elizabeth R. Plimack, Alexandre Lambert, Sumanta K. Pal, Margitta Retz and Daniel A. Vaena and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Abdel Saci

32 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Abdel Saci United States	16	2.1k	1.3k	802	756	754	32	3.2k
Cristina Cruz Spain	15	2.8k 1.3×	634 0.5×	922 1.1×	657 0.9×	1.2k 1.6×	36	3.7k
Yuko Mataki Japan	27	1.7k 0.8×	685 0.5×	820 1.0×	654 0.9×	532 0.7×	117	2.7k
Florian Gebauer Germany	27	1.4k 0.7×	688 0.5×	638 0.8×	728 1.0×	303 0.4×	113	2.3k
Zachary Boyd United States	14	2.3k 1.1×	705 0.5×	1.1k 1.3×	650 0.9×	1.2k 1.6×	27	3.7k
Xiaotao Qu United States	15	1.3k 0.6×	913 0.7×	581 0.7×	554 0.7×	580 0.8×	28	2.3k
Yoshihiro Miyasaka Japan	28	1.5k 0.7×	1.2k 0.9×	505 0.6×	724 1.0×	182 0.2×	100	2.4k
Íñigo Espinosa Spain	27	919 0.4×	440 0.3×	976 1.2×	865 1.1×	577 0.8×	56	2.9k
Paul E. Oberstein United States	14	2.2k 1.0×	388 0.3×	934 1.2×	243 0.3×	625 0.8×	70	2.8k
Ruth Perets Israel	18	1.3k 0.6×	414 0.3×	914 1.1×	546 0.7×	492 0.7×	61	2.7k
Akihito Kawazoe Japan	27	3.1k 1.4×	913 0.7×	647 0.8×	1.8k 2.4×	1.1k 1.5×	101	4.4k

Countries citing papers authored by Abdel Saci

Since Specialization

Citations

This map shows the geographic impact of Abdel Saci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdel Saci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdel Saci more than expected).

Fields of papers citing papers by Abdel Saci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abdel Saci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdel Saci. The network helps show where Abdel Saci may publish in the future.

Co-authorship network of co-authors of Abdel Saci

This figure shows the co-authorship network connecting the top 25 collaborators of Abdel Saci. A scholar is included among the top collaborators of Abdel Saci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdel Saci. Abdel Saci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Wungki, Anup Kasi, Alexander I. Spira, et al.. (2024). 608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S486–S487. 15 indexed citations

Hodi, F. Stephen, Jedd D. Wolchok, Dirk Schadendorf, et al.. (2021). TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research. 9(10). 1202–1213. 76 indexed citations

Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2020). Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical Cancer Research. 26(19). 5120–5128. 83 indexed citations

Goswami, Sangeeta, Yulong Chen, Swetha Anandhan, et al.. (2020). ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine. 12(548). 92 indexed citations

Sharma, Padmanee, Russell K. Pachynski, Vivek Narayan, et al.. (2020). Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 38(4). 489–499.e3. 257 indexed citations

Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616. 178 indexed citations

Wang, Li, Yixuan Gong, Abdel Saci, et al.. (2019). Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology. 76(5). 599–603. 89 indexed citations

Hodi, F. Stephen, Jedd D. Wolchok, Dirk Schadendorf, et al.. (2019). Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. Clinical Trials. CT037–CT037. 4 indexed citations

Wang, Rui, Abdel Saci, Amit Roy, et al.. (2019). Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma. Cancer Research. 79(13_Supplement). 2273–2273. 1 indexed citations

10.

Wang, Rui, Abdel Saci, Xiaozhong Qian, et al.. (2019). A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma. Clinical Pharmacology & Therapeutics. 107(4). 978–987. 28 indexed citations

11.

Hodi, F. Stephen, Jedd D. Wolchok, Dirk Schadendorf, et al.. (2019). Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. Cancer Research. 79(13_Supplement). CT037–CT037. 14 indexed citations

12.

Wang, Li, Abdel Saci, Péter M. Szabó, et al.. (2018). EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications. 9(1). 3503–3503. 216 indexed citations

13.

Lebbé, Célèste, Nicolás Meyer, Laurent Mortier, et al.. (2018). Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Annals of Oncology. 29. viii737–viii737. 3 indexed citations

14.

Rosenberg, Jonathan E., Padmanee Sharma, Filippo de Braud, et al.. (2018). Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. Annals of Oncology. 29. viii725–viii725. 10 indexed citations

15.

Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2017). Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study. Annals of Oncology. 28. v296–v297. 49 indexed citations

16.

Galsky, Matthew D., et al.. (2017). Epithelial-mesenchymal transition (EMT), T cell infiltration, and outcomes with nivolumab (nivo) in urothelial cancer (UC). Annals of Oncology. 28. v297–v297. 9 indexed citations

17.

Sharma, Padmanee, Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 18(3). 312–322. 1203 indexed citations breakdown →

18.

Galsky, Matt D., Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2016). Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Annals of Oncology. 27. vi567–vi567. 23 indexed citations

19.

Chew, Su Kit, Dong Lu, Lia S. Campos, et al.. (2014). Polygenic in vivovalidation of cancer mutations using transposons. Genome biology. 15(9). 455–455. 3 indexed citations

20.

Scott, Kenneth L., Omar Kabbarah, Mei‐Chih Liang, et al.. (2009). GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 459(7250). 1085–1090. 297 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact